G
Gianfranco Ferraccioli
Researcher at Catholic University of the Sacred Heart
Publications - 416
Citations - 30532
Gianfranco Ferraccioli is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 70, co-authored 402 publications receiving 26515 citations. Previous affiliations of Gianfranco Ferraccioli include University of Perugia & University of Parma.
Papers
More filters
Journal ArticleDOI
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Daniel Aletaha,Tuhina Neogi,Alan J. Silman,Julia Funovits,David T. Felson,Clifton O. Bingham,Neal S. Birnbaum,Gerd Burmester,Vivian P. Bykerk,Marc D. Cohen,Bernard Combe,Karen H. Costenbader,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Johanna M. W. Hazes,Kathryn Hobbs,Tom W J Huizinga,Arthur Kavanaugh,Jonathan Kay,Tore K Kvien,Timothy J. Laing,Philip J. Mease,Henri A Ménard,Larry W. Moreland,Raymond L. Naden,Theodore Pincus,Josef S Smolen,Ewa Stanislawska-Biernat,Deborah P M Symmons,Paul P. Tak,Katherine S. Upchurch,Jiří Vencovský,Frederick Wolfe,Gillian A. Hawker +34 more
TL;DR: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.
Journal ArticleDOI
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Daniel Aletaha,Tuhina Neogi,Alan J. Silman,Julia Funovits,David T. Felson,Clifton O. Bingham,Neal S. Birnbaum,Gerd Burmester,Vivian P. Bykerk,Marc D. Cohen,Bernard Combe,Karen H. Costenbader,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Johanna M. W. Hazes,Kathryn Hobbs,Tom W J Huizinga,Arthur Kavanaugh,Jonathan Kay,Tore K Kvien,Timothy J. Laing,Philip J. Mease,Henri A Ménard,Larry W. Moreland,Raymond L. Naden,Theodore Pincus,Josef S Smolen,Ewa Stanislawska-Biernat,Deborah P M Symmons,Paul P. Tak,Katherine S. Upchurch,Jiří Vencovský,Frederick Wolfe,Gillian A. Hawker +34 more
TL;DR: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.
Journal ArticleDOI
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
Bernard Combe,Robert Landewé,Cédric Lukas,Horatio D Bolosiu,F. C. Breedveld,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Jmw Hazes,Lars Klareskog,Klaus P Machold,Emilio Martín-Mola,Henrik Nielsen,Alan J. Silman,Josef S Smolen,Hasan Yazici +15 more
TL;DR: 12 key recommendations for the management of early arthritis or early rheumatoid arthritis were developed, based on evidence in the literature and expert consensus, in accordance with EULAR's "standardised operating procedures".
Journal ArticleDOI
Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
Francesco Zaja,Salvatore De Vita,Salvatore De Vita,Cesare Mazzaro,Cesare Mazzaro,S. Sacco,S. Sacco,Daniela Damiani,Daniela Damiani,Ginevra De Marchi,Ginevra De Marchi,Angela Michelutti,Angela Michelutti,Michele Baccarani,Michele Baccarani,Renato Fanin,Renato Fanin,Gianfranco Ferraccioli,Gianfranco Ferraccioli +18 more
TL;DR: Rituximab may represent a safe and effective alternative to standard immunosuppression in type II MC and is effective on skin vasculitis manifestations, subjective symptoms of peripheral neuropathy, low-grade B-cell lymphoma, arthralgias, and fever.
Journal ArticleDOI
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
Antonio Naranjo,Tuulikki Sokka,Miguel Ángel Descalzo,Jaime Calvo-Alén,Kim Hørslev-Petersen,Reijo Luukkainen,Bernard Combe,Gerd R Burmester,Joe Devlin,Gianfranco Ferraccioli,Alessia Morelli,Monique Hoekstra,Maria Majdan,Stefan Sadkiewicz,Miguel Belmonte,Ann Carin Holmqvist,Ernest Choy,Recep Tunc,Aleksander Dimic,Martin J. Bergman,Sergio Toloza,Theodore Pincus +21 more
TL;DR: Extended use of treatments such as methotrexate, sulfasalazine, leflunomide, glucocorticoids, and tumor necrosis factor-alpha blockers appears to be associated with a reduced risk of CV disease.